Palatin Shelves PL7737, Doubles Down on Next-Gen MC4R Agonists to Escape First-Generation Trap

As investors flee the stock, management argues superior selectivity will win the rare obesity race.

PTN · Earnings Call · 2026-05-13

The Pivot

Palatin Technologies, the micro-cap biotech focused on melanocortin-4 receptor (MC4R) agonists, reported its fiscal Q3 2026 results with a decisive strategic pivot: the company is discontinuing its lead oral small molecule PL7737 and redirecting resources toward next-generation compounds and a once-weekly peptide. The rationale, as CEO Carl Spana put it, is that “We're not going to be first to market in this space. So we really want to make sure we have best-in-class compounds.” — Carl Spana, CEO and President · 2026-05-13 The goal, stated earlier in the call, is “to develop best-in-class melanocortin-4 receptor agonist for the treatment of rare syndromic and genetic obesity disorders.” — Carl Spana, CEO and President · 2026-05-13 The decision was multifactorial. PL7737 had shown promising profile, but management felt it wouldn't meet the bar for MCR1 activity selectivity — a key driver of hyperpigmentation. During the quarter, they observed that backup compounds were achieving "verging on the almost elimination of MCR1 activity," making them significantly cleaner for chronic use. The company also cited the need to focus on the peptide program, which offers a once-weekly injection, a major usability advantage over daily injectables like the current approved therapy, setmelanotide.

What's Different

The new emphasis is on the treatment profile — balancing efficacy with tolerability and patient convenience. In the Q&A, Spana outlined how they aim to control pharmacokinetics to avoid spikes in drug exposure that can drive side effects: “I think the understanding that the PK parameters of these compounds have to put them in a range where we don't need to go to levels of drug exposure that exceed the therapeutic window so that we can eliminate or drastically reduce the potential side effects...” — Carl Spana, CEO and President · 2026-05-13 This focus on drug-like characteristics echoes the company's prior statements about designing better molecules. Two quarters earlier, management had already flagged this philosophy: “So we control potential GI side effects through a variety of mechanisms, not the least of which is the way the product is administered and absorbed.” — Carl Spana · 2026-02-17 That theme has now become central to the entire pipeline strategy. The competitive landscape is dominated by Rhythm Pharmaceuticals, which markets setmelanotide and is developing a weekly peptide (LB54640) and an oral small molecule (bivamelagon). Palatin acknowledges it is years behind in approved indications but argues that its next-gen compounds will capture share through better selectivity and usability. As Spana put it:

We're not all that far behind and you're coming -- and you're trying to come in with a better candidate and a better product. And I think that's the more important part. Who's going to have the compounds that really help to solve this issue with better patient compliance and better patient usability, maintaining good efficacy.
Carl Spana, CEO and President · 2026-05-13

Financial Position

Financially, the company tapped a mix of partnerships to fund operations. Boehringer Ingelheim collaboration brought in $8.8M in upfront and milestone payments in late 2025, and the sublicense of PL-9643 to Altanispac Labs added $3.8M in January 2026. This non-dilutive capital supports the pipeline while the company burns through roughly $4.4M per quarter. As of March 31, 2026, Palatin had $10.2M in cash plus $2.2M in receivables, and management expressed confidence in funding operations through June 2027, assuming disciplined expense control. Total revenue of $3.9M in Q3 FY26, up from zero a year earlier, was almost entirely collaboration and license revenue, while total operating expenses held at $5.5M. This is a company with a market cap of just $26M and a stock that has lost 46% over the past 90 days, trading near multi-year lows. The recent drawdown from an April high is 56.9%, reflecting investor skepticism about the company's ability to execute in a competitive field. Yet the pivot is a bet that the next-gen compounds will be differentiated enough to justify the wait.

The Bottom Line

Palatin is making a high-stakes bet that a better mouse trap will win the rare obesity market, even if it means starting behind. The strategic decision to shelve PL7737 and push forward with more selective candidates is a clear acknowledgment that first-mover advantage matters less than product quality in a field where chronic treatment and patient compliance are paramount. With the peptide IND on track for Q4 2026 and an oral small molecule for H1 2027, the next 12 months will prove whether this pivot pays off. For investors, the risk is palpable, but the potential upside is a differentiated therapy that could redefine the MC4R class.